

Technology Advisory Committee A Interests Register

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

Publication Date: 18/08/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Dominic Pivonka	TA Committee A Member	Direct - financial	Mr Pivonka's employer, AbbVie, has an treatment being investigated in early phase studies for the treatment of multiple cancers including cutaneous T-cell lymphoma. It is an oral treatment called Venetoclax which is currently licensed in blood cancer. This is a systemic treatment used in advanced disease and as such, it would not be a competitor for chlormethine gel.	NA	14/05/2021	NA	It was agreed that this declaration was not a conflict and Mr Pivonka participated in the meeting as usual.
Professor Julia Scarisbrick	Clinical Expert	Direct - financial	Paid advisory/consultancy roles for both Recordati Rare Diseases and Helsinn Healthcare. This included a speaker engagement in 2019 for the European Organisation for Research and Treatment of Cancer, medical lectures in the field of MF-CTCL, providing advice	NA	21/11/2019	NA	It was agreed that this declaration would not prevent Professor Scarisbrick from providing expert advice to the committee.

			on the design of QoL vignette proxy study and healthcare resource utilisation survey designs for the UK and participation on advisory boards and expert group participations.				
Mr Stephen Scowcroft	Patient Expert	Indirect interest	Employed by Lymphoma Action, who receive financial support to fund their work programme from pharmaceutical companies including Recordati Rare Diseases.	NA	06/06/2020	NA	It was agreed that this declaration would not prevent Mr Scowcroft from providing expert advice to the committee.